NHAS
Novo Holdings A/S Portfolio holdings
AUM
$1.42B
This Quarter Return
-1.22%
1 Year Return
+12.08%
3 Year Return
+99.82%
5 Year Return
+98.46%
10 Year Return
+612.59%
AUM
$1.35B
AUM Growth
+$1.35B
(+4.6%)
Cap. Flow
+$121M
Cap. Flow
% of AUM
8.91%
Top 10 Holdings %
Top 10 Hldgs %
58.23%
Holding
42
New
1
Increased
8
Reduced
3
Closed
2
Top Buys
| 1 |
Brookfield
BN
|
$102M |
| 2 |
Brookfield Asset Management
BAM
|
$20.9M |
| 3 |
Cable One
CABO
|
$15M |
| 4 |
Inspire Medical Systems
INSP
|
$5.46M |
| 5 |
BPMC
Blueprint Medicines
BPMC
|
$3.83M |
Top Sells
| 1 |
VERV
Verve Therapeutics
VERV
|
$9.38M |
| 2 |
CYT
Cyteir Therapeutics, Inc. Common Stock
CYT
|
$8.48M |
| 3 |
GRTX
Galera Therapeutics, Inc. Common Stock
GRTX
|
$6.55M |
| 4 |
CBAY
Cymabay Therapeutics
CBAY
|
$6.46M |
| 5 |
Mirum Pharmaceuticals
MIRM
|
$5.82M |
Sector Composition
| 1 | Healthcare | 51.32% |
| 2 | Technology | 24.11% |
| 3 | Financials | 10.51% |
| 4 | Industrials | 5.46% |
| 5 | Communication Services | 5.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Brookfield
BN
$98.3B
| $121M | 8.97% |
3,880,230
+3,253,023
| +519% | +$102M |
|
2
ASML
ASML
$292B
| $116M | 8.6% |
197,760
| – | – |
|
3
Salesforce
CRM
$245B
| $108M | 7.95% |
530,500
| – | – |
|
4
Corcept Therapeutics
CORT
$7.35B
| $92M | 6.8% |
3,377,768
| – | – |
|
5
LanzaTech
LNZA
$49.1M
| $73.9M | 5.46% |
15,814,845
| – | – |
|
|
6
Cable One
CABO
$909M
| $72.9M | 5.39% |
118,403
+24,300
| +26% | +$15M |
|
7
TSMC
TSM
$1.2T
| $61.8M | 4.56% |
710,780
| – | – |
|
8
Disc Medicine
IRON
$2.07B
| $51.2M | 3.79% |
1,090,772
| – | – |
|
|
9
Mirum Pharmaceuticals
MIRM
$3.71B
| $47.4M | 3.5% |
1,500,000
-184,193
| -11% | -$5.82M |
|
10
Alibaba
BABA
$322B
| $43.4M | 3.21% |
500,827
| – | – |
|
11
Vaxcyte
PCVX
$4B
| $43.1M | 3.18% |
845,000
| – | – |
|
12
Arcellx
ACLX
$3.85B
| $38.6M | 2.85% |
1,075,000
+75,000
| +8% | +$2.69M |
|
13
Apple
AAPL
$3.45T
| $37.9M | 2.8% |
221,460
| – | – |
|
14
BioMarin Pharmaceuticals
BMRN
$11.2B
| $35.4M | 2.62% |
400,000
| – | – |
|
15
Edgewise Therapeutics
EWTX
$1.51B
| $34.8M | 2.57% |
6,071,703
| – | – |
|
|
SGEN
16
DELISTED
Seagen Inc. Common Stock
SGEN
| $33.9M | 2.51% |
159,986
| – | – |
|
17
Insmed
INSM
$28.8B
| $33.8M | 2.5% |
1,339,304
| – | – |
|
18
Crinetics Pharmaceuticals
CRNX
$2.92B
| $32.7M | 2.42% |
1,100,000
| – | – |
|
19
Pharvaris
PHVS
$1.39B
| $27.7M | 2.05% |
1,329,325
| – | – |
|
|
BPMC
20
DELISTED
Blueprint Medicines
BPMC
| $26.4M | 1.95% |
525,000
+76,196
| +17% | +$3.83M |
|
21
Amicus Therapeutics
FOLD
$2.34B
| $25.5M | 1.88% |
2,095,900
| – | – |
|
|
OKUR
22
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$37.2M
| $25.3M | 1.87% |
3,330,377
| – | – |
|
|
CBAY
23
DELISTED
Cymabay Therapeutics
CBAY
| $23.4M | 1.73% |
1,566,521
-433,479
| -22% | -$6.46M |
|
24
Alnylam Pharmaceuticals
ALNY
$58.5B
| $21M | 1.55% |
118,383
| – | – |
|
|
25
Brookfield Asset Management
BAM
$97B
| $20.9M | 1.55% |
+627,207
| New | +$20.9M |
|